NASDAQ:ACXP

Acurx Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ACXP

*Your capital is at risk

$1.75

-0.0500 (-2.78%)

At Close: Jun 03, 2026

Acurx Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 4.7M and sold 220K ACXP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	4.7M shares
● Sell	220K shares
94% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 23, 2024 Buy	Stock Option A-Award	Deluccia Robert J	Director	250 000 Value: $787.5K
Feb 23, 2024 Buy	Stock Option A-Award	Luci David P President And CEO	CEO / President	250 000 Value: $787.5K
Feb 23, 2024 Buy	Stock Option A-Award	Shawah Robert G. Chief Financial Officer	C-Suite Officer	145 000 Value: $456.8K
Feb 23, 2024 Buy	Stock Option A-Award	Deluccia Robert J	Director	250 000 Value: $787.5K
Jan 19, 2024 Buy	Common Stock M-Exempt	Sailer Carl Director	Director	19 737 Value: $70.1K
Jan 19, 2024 Buy	Warrants for Common Stock M-Exempt	Sailer Carl Director	Director	19 737 Value: $70.1K
Jan 19, 2024 Buy	Common Stock M-Exempt	Sailer Carl Director	Director	19 737 Value: $70.1K
Jan 19, 2024 Buy	Warrants for Common Stock M-Exempt	Sailer Carl Director	Director	19 737 Value: $70.1K
Jan 03, 2024 Buy	Common Stock M-Exempt	Deluccia Robert J	Director	19 737 Value: $70.1K
Jan 03, 2024 Buy	Warrants for Common Stock M-Exempt	Deluccia Robert J	Director	19 737 Value: $70.1K
Jan 03, 2024 Buy	Common Stock M-Exempt	Luci David P President And CEO	CEO / President	19 737 Value: $70.1K
Jan 03, 2024 Buy	Warrants for Common Stock M-Exempt	Luci David P President And CEO	CEO / President	19 737 Value: $70.1K
Jan 03, 2024 Buy	Common Stock M-Exempt	Deluccia Robert J	Director	19 737 Value: $70.1K
Jan 03, 2024 Buy	Warrants for Common Stock M-Exempt	Deluccia Robert J	Director	19 737 Value: $70.1K
Jan 03, 2024 Buy	Common Stock M-Exempt	Luci David P President And CEO	CEO / President	19 737 Value: $70.1K
Jan 03, 2024 Buy	Warrants for Common Stock M-Exempt	Luci David P President And CEO	CEO / President	19 737 Value: $70.1K
Dec 22, 2023 Sell	Common Stock G-Gift	Deluccia Robert J	Director	30 000 Value: $0
Dec 22, 2023 Sell	Common Stock G-Gift	Deluccia Robert J	Director	30 000 Value: $0
Dec 12, 2023 Sell	Common Stock G-Gift	Deluccia Robert J	Director	40 000 Value: $0
Dec 12, 2023 Sell	Common Stock G-Gift	Deluccia Robert J	Director	40 000 Value: $0
Jun 15, 2023 Buy	Stock Option A-Award	Donohue James J. Director	Director	10 000 Value: $27.5K
Jun 15, 2023 Buy	Stock Option A-Award	Harrison Thomas L Director	Director	10 000 Value: $27.5K
Jun 15, 2023 Buy	Stock Option A-Award	Dean Jack H Director	Director	10 000 Value: $27.5K
Jun 15, 2023 Buy	Stock Option A-Award	Sailer Carl Director	Director	10 000 Value: $27.5K
Jun 15, 2023 Buy	Stock Option A-Award	Scodari Joseph C Director	Director	10 000 Value: $27.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ACURX PHARMACEUTICALS, INC.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bac...

Read Full Profile Here